Harmony Capital Surpluse from 2010 to 2024

HRMY Stock  USD 34.67  1.08  3.02%   
Harmony Biosciences Capital Surpluse yearly trend continues to be fairly stable with very little volatility. Capital Surpluse will likely drop to about 696.9 M in 2024. During the period from 2010 to 2024, Harmony Biosciences Capital Surpluse regression line of annual values had r-squared of  0.52 and arithmetic mean of  615,173,793. View All Fundamentals
 
Capital Surpluse  
First Reported
2010-12-31
Previous Quarter
776.4 M
Current Value
696.9 M
Quarterly Volatility
57.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Harmony Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Harmony Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 28.4 M, Depreciation And Amortization of 14.7 M or Interest Expense of 17.9 M, as well as many indicators such as Price To Sales Ratio of 3.14, Dividend Yield of 0.0 or PTB Ratio of 4.32. Harmony financial statements analysis is a perfect complement when working with Harmony Biosciences Valuation or Volatility modules.
  
Check out the analysis of Harmony Biosciences Correlation against competitors.

Latest Harmony Biosciences' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Harmony Biosciences Holdings over the last few years. It is Harmony Biosciences' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Harmony Biosciences' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Harmony Capital Surpluse Regression Statistics

Arithmetic Mean615,173,793
Geometric Mean612,880,468
Coefficient Of Variation9.38
Mean Deviation43,706,364
Median585,374,000
Standard Deviation57,724,197
Sample Variance3332.1T
Range191M
R-Value0.72
Mean Square Error1739.4T
R-Squared0.52
Significance0
Slope9,265,316
Total Sum of Squares46649.2T

Harmony Capital Surpluse History

2024696.9 M
2023776.4 M
2022675.1 M
2021640.1 M

About Harmony Biosciences Financial Statements

Harmony Biosciences investors use historical fundamental indicators, such as Harmony Biosciences' Capital Surpluse, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Harmony Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse776.4 M696.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Harmony Stock Analysis

When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.